These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37752231)

  • 1. The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300.
    Brown AD; Lynch K; Langelaan DN
    Sci Rep; 2023 Sep; 13(1):16094. PubMed ID: 37752231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor.
    Brown AD; Vergunst KL; Branch M; Blair CM; Dupré DJ; Baillie GS; Langelaan DN
    Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119520. PubMed ID: 37353163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
    Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
    Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Catenin interacts with the TAZ1 and TAZ2 domains of CBP/p300 to activate gene transcription.
    Brown AD; Cranstone C; Dupré DJ; Langelaan DN
    Int J Biol Macromol; 2023 May; 238():124155. PubMed ID: 36963539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into TAZ2 domain-mediated CBP/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A.
    Lochhead MR; Brown AD; Kirlin AC; Chitayat S; Munro K; Findlay JE; Baillie GS; LeBrun DP; Langelaan DN; Smith SP
    J Biol Chem; 2020 Mar; 295(13):4303-4315. PubMed ID: 32098872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators.
    Vachtenheim J; Sestáková B; Tuhácková Z
    Pigment Cell Res; 2007 Feb; 20(1):41-51. PubMed ID: 17250547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
    Jenkins LM; Yamaguchi H; Hayashi R; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Mazur SJ
    Biochemistry; 2009 Feb; 48(6):1244-55. PubMed ID: 19166313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MITF: master regulator of melanocyte development and melanoma oncogene.
    Levy C; Khaled M; Fisher DE
    Trends Mol Med; 2006 Sep; 12(9):406-14. PubMed ID: 16899407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP.
    Lee CW; Arai M; Martinez-Yamout MA; Dyson HJ; Wright PE
    Biochemistry; 2009 Mar; 48(10):2115-24. PubMed ID: 19220000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MITF and TFEB cross-regulation in melanoma cells.
    Ballesteros-Álvarez J; Dilshat R; Fock V; Möller K; Karl L; Larue L; Ögmundsdóttir MH; Steingrímsson E
    PLoS One; 2020; 15(9):e0238546. PubMed ID: 32881934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MITF family of transcription factors: Role in endolysosomal biogenesis, Wnt signaling, and oncogenesis.
    Ploper D; De Robertis EM
    Pharmacol Res; 2015 Sep; 99():36-43. PubMed ID: 26003288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
    Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylation reprograms MITF target selectivity and residence time.
    Louphrasitthiphol P; Loffreda A; Pogenberg V; Picaud S; Schepsky A; Friedrichsen H; Zeng Z; Lashgari A; Thomas B; Patton EE; Wilmanns M; Filippakopoulos P; Lambert JP; Steingrímsson E; Mazza D; Goding CR
    Nat Commun; 2023 Sep; 14(1):6051. PubMed ID: 37770430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of the disordered p53 transactivation domain by the transcriptional adapter zinc finger domains of CREB-binding protein.
    Krois AS; Ferreon JC; Martinez-Yamout MA; Dyson HJ; Wright PE
    Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1853-62. PubMed ID: 26976603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiT/TFE Family Renal Cell Carcinoma.
    Tang J; Baba M
    Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains.
    Wojciak JM; Martinez-Yamout MA; Dyson HJ; Wright PE
    EMBO J; 2009 Apr; 28(7):948-58. PubMed ID: 19214187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dominant negative mutant of microphthalmia transcription factor (MITF) lacking two transactivation domains suppresses transcription mediated by wild type MITF and a hyperactive MITF derivative.
    Vachtenheim J; Drdová B
    Pigment Cell Res; 2004 Feb; 17(1):43-50. PubMed ID: 14717844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
    Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
    Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CBP/p300 as a co-factor for the Microphthalmia transcription factor.
    Sato S; Roberts K; Gambino G; Cook A; Kouzarides T; Goding CR
    Oncogene; 1997 Jun; 14(25):3083-92. PubMed ID: 9223672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response.
    Pfitzner E; Jähne R; Wissler M; Stoecklin E; Groner B
    Mol Endocrinol; 1998 Oct; 12(10):1582-93. PubMed ID: 9773981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.